CXCL8 and tuberculosis: PBMC from TB patients treated with a specific NF-κB inhibitors, JSH-23 (50 μM) and Helenalin (0.5 μM), suppressed the release of IP-10/CXCL10 (293.2±26.9 pg/ml and 12.5±5.5 pg/ml, respectively, p<0.001) and IL-8/CXCL8 (2355.0±232.8 pg/ml and 2355±232.8 pg/ml, respectively, p<0.05) than those of control (695.9±22.6 and 4435.0±215.6 pg/ml n = 5, respectively) (Figure 2B), indicating the release of IP-10/CXCL10 and IL-8/CXCL8 is mediated via NF-κB.